Top Markets
Coin of the day
Fresh Tracks Therapeutics, Inc. Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc.

FRTX
Rangering i aksjer #36397
Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused... Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.
Aksjekurs
$0.94
Sist synkronisert: 2025-02-28
Markedsverdi
$2.73M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Fresh Tracks Therapeutics, Inc. (FRTX)

Kategori

Inntekter for Fresh Tracks Therapeutics, Inc. (FRTX)
Inntekter i Dec 2023 TTM: $8.01M
Ifølge de nyeste økonomiske rapportene til Fresh Tracks Therapeutics, Inc. er selskapets nåværende inntekter (TTM) $8.01M. I 2022 hadde selskapet inntekter på $6.94M en økning sammenlignet med inntektene i 2021, som var $404.00K. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Fresh Tracks Therapeutics, Inc. fra 2000 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $8.01M 0.00%
2023 $8.01M 15.31%
2022 $6.94M 1,618.56%
2021 $404.00K -77.83%
2020 $1.82M -76.99%
2019 $7.92M 388.10%
2018 $1.62M -88.26%
2017 $13.82M -4.90%
2016 $14.53M -30.64%
2015 $20.95M 37.67%
2014 $15.22M 97.16%
2013 $7.72M -55.94%
2012 $17.52M -41.64%
2011 $30.02M 244.60%
2010 $8.71M -31.33%
2009 $12.69M 59.45%
2008 $7.96M 44.34%
2007 $5.51M -62.61%
2006 $14.74M 22.80%
2005 $12.00M -17.48%
2004 $14.55M 80.05%
2003 $8.08M 15.29%
2002 $7.01M -38.35%
2001 $11.37M 49.16%
2000 $7.62M 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$12.62B 157,585.49%
US
$6.02B 75,109.68%
NL
- -
CH
- -
KR
$10.11B 126,190.12%
BE